Key Points CRISPR Therapeutics' sole approved product doesn't generate much sales yet. It does have some pipeline candidates that could make progress over the next year. Though the risks are somewhat high, CRISPR has substantial upside potential. 10 stocks we like better than CRISPR Therapeutics › Though it started the year strong, CRISPR Therapeutics (NASDAQ: CRSP) is experiencing a pullback. Over the past month, shares of the gene-editing specialist are down 23%. But there is plenty of upside f ...